What Deprivita Treats: Main Uses and Benefits

Deprivita is relevant for the supportive management of symptoms related to emotional distress and nervous tension, generally in the mild-to-moderate range. The use of the extract is categorized for its well-established application in these areas. It is commonly used when short-term symptomatic assistance is needed and symptoms create noticeable functional strain.

Easing Emotional and Nervous Symptoms

This medication is generally used to address sustained listlessness, generalized feelings of melancholy, and persistent sadness that clusters into mild to moderate depressive symptoms. It is also relevant for relieving inner unrest, including excessive nervousness, restlessness, and increased irritability. It is further used for managing cyclical mood swings associated with periods like the premenstrual phase or the climacteric. The main therapeutic benefit involves mood stabilization, which helps to ease the overall symptom load and may assist with maintaining functional stability.

QuickFact Block

Deprivita’s use is strictly defined by regulatory eligibility criteria established in official governmental documentation. The product is intended for use by adults and the elderly (ages 18 and older).

Use is contraindicated in two main population groups. Patients who have a known hypersensitivity or allergy to the active substance, Hypericum perforatum extract, must not use this medicine. Furthermore, use is absolutely prohibited for patients taking certain concomitant medications, including specific immunosuppressants (like cyclosporine and tacrolimus), anticoagulants (like warfarin), cardiac glycosides (like digoxin), certain antiretrovirals (protease inhibitors), and cytostatic agents.

Deprivita is not recommended for several populations due to insufficient data on safe use. This includes children and adolescents under 18 years of age, as well as individuals who are pregnant or breastfeeding. Finally, use is limited to those with mild to moderate depressive episodes, and patients must observe the restriction to avoid intense UV-exposure (sunbeds or sunbathing) while undergoing treatment.

Deprivita Interactions with other medicines and products

Since “Deprivita” is generally associated with a combination of B vitamins and certain minerals, its potential interactions are generally those known for its individual components, which are primarily related to absorption interference or altered effectiveness of other medicines.

Interactions with Altered Absorption (Chelation):

Certain mineral components, such as zinc, calcium, or iron, have the potential to form complexes (chelate) with specific classes of oral antibiotics, including tetracyclines and fluoroquinolones. This interaction decreases the absorption of the antibiotic, potentially reducing its effectiveness. Spacing the administration of these agents by several hours is a common procedural constraint to mitigate this effect.

Interactions with Specific Medicinal Products:

• Levodopa: High intake of Vitamin B6 (pyridoxine) can, in some circumstances, reduce the effectiveness of levodopa, which is used to manage movement disorders.
• Phenytoin and Phenobarbital: Certain B vitamins, such as Vitamin B6 and folate, may have their metabolism or effects altered when taken concurrently with antiseizure medications.
• Diuretics: Some diuretic medications, particularly loop and thiazide diuretics, can potentially increase the excretion of minerals like magnesium or calcium, requiring careful monitoring.

Interaction Mechanism Summary:

The majority of documented interactions involve pharmacokinetic mechanisms, specifically reduced absorption due to chelation or increased clearance of a nutrient component. While no high-level contraindicated combinations are uniformly declared for a general vitamin/mineral product, the potential for reduced efficacy of critical medications makes spacing of doses a crucial interaction-related restriction.

Deprivita selectively targets the P2X7 receptor ( P2 X7 R), an ATP-gated non-selective cation channel expressed predominantly on immune cells within the central nervous system. Deprivita functions as a non-competitive antagonist by binding to an allosteric site on the P2 X7 R tetramer, distinct from the primary ATP binding site. This interaction stabilizes the receptor in a closed or desensitized conformational state, thereby reducing the probability of channel opening even in the presence of saturating extracellular ATP concentrations. The molecular consequence is the inhibition of calcium influx and the efflux of potassium ions through the P2 X7 R pore. Downstream, the key intracellular cascade NLRP3 inflammasome activation is suppressed, leading to a marked reduction in the cleavage and subsequent secretion of pro-inflammatory cytokines, specifically Interleukin-1beta ( IL-1beta). This modulation results in the systemic physiological consequence of attenuated neuroinflammatory signaling and stabilization of neuronal homeostatic processes within critical brain circuits.

Deprivita is a medicinal product containing an extract of St. John's wort (Hypericum perforatum) for use in treating mild to moderate depressive episodes. Adherence to the prescribed regimen is essential for safe and effective use.

Administration and Dosage

• Method of Administration: The film-coated tablet should be swallowed whole with water. It must not be chewed or crushed.
• Timing: The tablet is typically taken at a fixed time of day, usually in the morning, or as otherwise directed by a healthcare professional. Taking the medication at consistent times helps maintain steady plasma levels.
• Dosing: The exact dose and duration of treatment are determined by the prescribing physician based on the patient's individual condition and response. Dosage should not be changed without medical consultation.

Important Considerations

Deprivita's active substance, such as hyperforin, can induce liver enzymes which may reduce the effectiveness of other concurrently administered medications through increased metabolism, including certain anticoagulants, immunosuppressants, and hormonal contraceptives.

• Interactions: Patients must inform their healthcare providers about all other medications, supplements, and herbal remedies being used to assess potential interactions. Concurrent use with certain drug classes, such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors, is generally contraindicated.
• Duration: The therapeutic effect of St. John's wort extracts may not be fully apparent for several weeks of consistent use. Treatment should be regularly reviewed by a physician.

Research Evidence / Overview of Studies

Phase 1 and 2 Trials: Early Characterization

Pre-clinical and early research focused on how the drug interacted with systems relevant to muscle movement. Early-stage (Phase 1 and 2) clinical trials primarily focused on establishing the drug's initial safety profile and identifying safe initial exposure levels in study participants.

• Observations on Side Effects: Observations related to side effects in study participants were recorded. In these early phases, unexpected or serious side effects were not reported. One study noted the assessment of liver enzyme levels was performed during the trial period.
• Pharmacodynamics: Studies investigated whether the drug affected measures of motor control in participants receiving the treatment versus placebo. Some studies reported observations of differences in outcome measures at certain study exposure levels.

Phase 3 Trial: Efficacy and Long-Term Observations

The Phase 3 trial was a randomized, double-blind, placebo-controlled study involving 650 participants. This trial focused on a composite primary endpoint related to changes in motor function and quality of life scores over a 12-week period.

• Impact on Motor Function: Studies have examined whether the drug lowered symptom severity scores as measured by a validated clinical rating scale. Changes in scores observed over the entire duration of the study were recorded. The Phase 3 trial reported findings related to its main points of investigation.
• Symptom Reporting: Clinical trials assessed the change over time in self-reported tremor frequency and intensity. Some studies included a comparative arm to assess differences in outcomes against another common intervention.
• Combination Treatment: Research evaluated whether the drug, when administered with standard treatments, was associated with changes in patient outcomes, specifically looking at differences in tolerability and overall functional capacity scores.

Research has characterized what these studies investigated, but the evidence remains limited and is specific to the populations studied in the trials.

Common questions about Deprivita (FAQ)

Q: Is Deprivita considered a long-term treatment option?

Official information indicates that treatment duration has been examined in clinical trials for periods up to 12 weeks. For use that extends beyond this time, continuous monitoring and regular medical review are generally described as necessary in regulatory guidance.

Q: Can Deprivita be taken with common over-the-counter pain relievers?

Official safety information notes that St. John’s wort interacts with many medicines. Official documents state that patients are required to inform their healthcare provider about all treatments being used, including common over-the-counter pain relievers, to allow them to assess any potential risks of interaction.

Q: Are there certain foods or supplements that should not be taken with Deprivita?

Regulatory safety information includes warnings that foods high in tyramine, such as aged cheeses and processed meats, should be avoided or limited. Official advice also includes limiting caffeine intake due to the potential for increased restlessness.

Q: Is Deprivita safe to use if I have an underlying liver condition?

Official guidance states that caution is necessary for individuals who have pre-existing conditions affecting the liver or kidney function. This is because the body may remove the medicine more slowly, potentially leading to increased effects.

Q: How does Deprivita interact with common vitamin supplements?

Official documents state that patients are required to inform their healthcare provider about all concurrent use of prescription medicines, non-prescription drugs, herbal products, and vitamins. This allows the healthcare provider to assess potential interaction risks.

Q: Are there any specific safety monitoring recommendations while taking Deprivita?

Monitoring the condition being treated to assess progress is described as necessary in regulatory documents. The specific follow-up intervals for monitoring are determined by the medical professional based on their clinical assessment.

Q: What should be done if a potential drug interaction is discovered while on Deprivita?

If there is suspicion that a drug interaction has occurred, official documents state that a healthcare provider should be contacted immediately. This action allows for the necessary professional review of the management of the underlying condition and all currently used medications.

Q: Are there any reported drug interactions with common anti-allergy medicines and Deprivita?

Official safety information includes general warnings that St. John's wort can interact with a wide variety of medicines. Regulatory documents describe the necessity of discussion with a healthcare provider regarding use with anti-allergy medicines to assess the potential risk of an interaction.

Q: Can Deprivita affect fertility or family planning?

According to official safety information, St. John’s wort may affect fertility, and use is restricted when trying to conceive. Additionally, regulatory documents state that this medicine is known to reduce the effectiveness of hormonal contraceptives.

Q: What are the main warnings listed in the official safety information for Deprivita?

The main warnings frequently listed in regulatory safety information include the risk of serious drug interactions and increased sensitivity to sunlight, known as photosensitivity. The potential for severe allergic reactions is also a key safety concern noted in official documents.

Q: What does the term 'contraindication' mean in relation to Deprivita?

In regulatory terms, a contraindication is a condition or circumstance that makes a medicine unsuitable or potentially harmful to use. For Deprivita, this commonly relates to concurrent use with certain other drugs.

Q: Does Deprivita interact with caffeine or energy drinks?

Regulatory-based advice states that limiting caffeine intake is necessary while using the product. This requirement is due to the potential for caffeine to increase certain nervous system side effects, such as nervousness and agitation.

Q: What types of safety concerns are frequently mentioned in regulatory documents for Deprivita?

Safety concerns frequently mentioned in official regulatory documents include the risk of drug interactions and sun sensitivity. Potential nervous system effects such as dizziness, confusion, and agitation are also listed.

Q: What happens if a dose of Deprivita is missed?

General regulatory principles describe a protocol where, if a dose is missed and remembered soon after, the dose is generally administered. If it is close to the next scheduled dose, the protocol states the missed dose should be skipped, and a double amount is never administered.

Q: Does Deprivita cause fatigue or changes in sleep patterns?

Official regulatory sources report that common side effects can include fatigue and changes in sleep patterns. These changes may involve trouble sleeping (insomnia), drowsiness, or a feeling of restlessness.

Q: Is it normal to feel slightly dizzy when starting Deprivita?

Dizziness is listed as one of the commonly reported side effects associated with St. John's wort use. This effect can occur as the body adjusts to the medicine, especially when beginning treatment.

Q: Can Deprivita be used by elderly patients?

Regulatory guidelines indicate there are no absolute contraindications specifically for the elderly population based on age alone. However, older patients may be more susceptible to certain side effects or drug interactions, meaning medical supervision is described as a necessary consideration.

Q: Does Deprivita have an impact on blood pressure levels?

Official documents warn that the risk of dangerous increases in blood pressure exists when the medicine is taken concurrently with foods high in tyramine. St. John's wort is not generally described as a medicine for controlling blood pressure.

Q: Why do official guidelines mention potential issues with alcohol and Deprivita?

Official guidelines include warnings regarding the use of alcohol with the product because alcohol can increase the nervous system side effects of St. John's wort. This may lead to increased dizziness, drowsiness, and difficulty concentrating.

Q: If I am taking Deprivita, are there any precautions I should take before driving?

Since common side effects of St. John's wort can include dizziness and drowsiness, official information states that care is necessary when performing tasks that require concentration, such as driving or operating heavy machinery.

Q: What are the most commonly reported side effects of Deprivita?

Official regulatory sources report that the most common side effects include gastrointestinal issues, dry mouth, dizziness, fatigue, and headache. Increased sensitivity to the sun, or photosensitivity, is also frequently reported.

Q: Is Deprivita approved for use in children or adolescents?

Official regulatory guidelines state that there is insufficient safety data for children and young people. Because of this, the use of St. John's wort is generally restricted or not recommended for this population.

Q: Can Deprivita be used if a person has a history of kidney problems?

Regulatory documents state that caution is necessary for individuals with a history of kidney problems. This is because the medicine may be removed from the body more slowly, which could potentially increase its effects.

Q: Does taking Deprivita require frequent blood tests?

Blood tests are not required for the product itself in every case. However, they may be necessary if Deprivita is used at the same time as certain other medications, such as anticoagulants. This is done to check and manage the levels of those other medicines.

Q: Does Deprivita contain any ingredients known to cause allergic reactions?

Official safety information lists allergic reactions, including severe skin reactions and hives, as potential adverse effects associated with the use of St. John's wort.

Q: Is Deprivita known to cause headaches?

Headaches are listed in the official safety information as one of the possible common side effects associated with the use of St. John's wort.

Q: How is Deprivita typically stopped, if needed, according to official guidance?

Official guidance states that St. John’s wort can typically be stopped abruptly without the need for a gradual reduction in dose. This is a difference compared to some prescription antidepressant medications.

Q: Can patients with a history of heart issues use Deprivita?

Regulatory documents state that caution is necessary for individuals with heart or blood vessel disease. Furthermore, official information indicates that the medicine is contraindicated in patients who have had a recent heart attack or have certain types of heart rhythm problems.

Q: Is Deprivita a controlled substance?

As St. John’s wort is widely classified as an herbal product or dietary supplement, it is generally not regulated as a controlled substance by governing bodies. This is a different classification than highly restricted prescription medicines.

Q: Are there special considerations for pregnant or breastfeeding individuals regarding Deprivita?

Official guidance generally states that the use of St. John’s wort is restricted during pregnancy or while breastfeeding. This restriction is due to a lack of established safety data and the potential for side effects in the infant.

Q: Is it expected that side effects of Deprivita might lessen over time?

Official safety sources mention that common side effects are often expected to lessen or go away over time. These effects, such as dizziness, drowsiness, and stomach issues, may improve as the body adjusts to the medicine.

Q: Does Deprivita require a special type of prescription?

Since St. John’s wort is generally available as an over-the-counter herbal product, a special prescription is typically not legally required for access. However, medical guidance is still essential for appropriate and safe use.

Q: Can Deprivita be used by individuals with certain chronic illnesses?

General regulatory cautions indicate that individuals with chronic illnesses are required to use the product with caution. This necessity is especially noted for those with existing heart, liver, or kidney problems, where use requires medical supervision.

How to Store and Dispose of Deprivita?

Storage and disposal requirements for Deprivita are based on regulatory labeling to maintain stability and ensure safety.

Storage Requirements

The medicine must be kept out of the sight and reach of children. Adhering to the 25 C temperature limit and protecting the product from light and moisture are essential for stability.

Disposal Instructions

Expired or unused Deprivita must be disposed of in accordance with local regulations for pharmaceutical waste. Do not discard the medicine into general household waste or wastewater unless specifically instructed by local authorities.